Reconvalescent blood products, Passive vaccine
| Zeile 16: | Zeile 16: | ||
{{tp|p=32219428|t=2020. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma |pdf=|usr=}} | {{tp|p=32219428|t=2020. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma |pdf=|usr=}} | ||
{{tp|p=32313872|t=ä. COVID-19 convalescent plasma transfusion |pdf=|usr=}} | {{tp|p=32313872|t=ä. COVID-19 convalescent plasma transfusion |pdf=|usr=}} | ||
| + | {{tp|p=32113510|t=2020. Convalescent plasma as a potential therapy for COVID-19 |pdf=|usr=}} | ||
| + | {{tp|p=C7158785|t=ä. Convalescent plasma: A possible treatment of COVID-19 in India |pdf=|usr=}} | ||
| + | {{tp|p=32343358|t=2020. Immunoglobulins or convalescent plasma to tackle COVID-19: buying time to save lives - current situation and perspectives |pdf=|usr=}} | ||
| + | {{tp|p=32253318|t=2020. Effectiveness of convalescent plasma therapy in severe COVID-19 patients |pdf=|usr=}} | ||
| + | {{tp|p=32345485|t=ä. Treatment for emerging viruses: Convalescent plasma and COVID-19 |pdf=|usr=}} | ||
| + | {{tp|p=32380316|t=ä. Convalescent plasma in Covid-19: Possible mechanisms of action |pdf=|usr=}} | ||
| + | {{tp|p=32359789|t=ä. COVID-19 Convalescent Plasma: Now Is the Time for Better Science |pdf=|usr=}} | ||
| + | {{tp|p=32359788|t=ä. Convalescent Plasma: Therapeutic Hope or Hopeless Strategy in the SARS-CoV-2 Pandemic |pdf=|usr=}} | ||
| + | {{tp|p=32217555|t=2020. Covid-19: FDA approves use of convalescent plasma to treat critically ill patients |pdf=|usr=}} | ||
| + | {{ttp|p=32369628|t=2020. Convalescent donor SARS-COV-2-specific cytotoxic T lymphocyte infusion as a possible treatment option for COVID-19 patients with severe disease has not received enough attention till date |pdf=|usr=}} | ||
Version vom 21. Juni 2020, 11:25 Uhr
32243945 ä. Treatment With Convalescent Plasma for Critically Ill Patients With SARS-CoV-2 Infection
32375025 ä. Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies
32344202 2020. Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development
32298745 ä. Successful treatment of plasma exchange followed by intravenous immunogloblin in a critically ill patient with 2019 novel coronavirus infection
32226289 2020. Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2
32218340 2020. Could Intravenous Immunoglobulin Collected from Recovered Coronavirus Patients Protect against COVID-19 and Strengthen the Immune System of New Patients?
32254064 2020. Deployment of convalescent plasma for the prevention and treatment of COVID-19
32305026 ä. Challenges of Convalescent Plasma Therapy on COVID-19
32167489 ä. The convalescent sera option for containing COVID-19
32348485 ä. Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in COVID-19 Patients
| 32249185 ä. Duration of serum neutralizing antibodies for SARS-CoV-2: Lessons from SARS-CoV infection |
32281317 2020. Use of Convalescent Plasma Therapy in Two COVID-19 Patients with Acute Respiratory Distress Syndrome in Korea
32219428 2020. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma
32313872 ä. COVID-19 convalescent plasma transfusion
32113510 2020. Convalescent plasma as a potential therapy for COVID-19
C7158785 ä. Convalescent plasma: A possible treatment of COVID-19 in India
32343358 2020. Immunoglobulins or convalescent plasma to tackle COVID-19: buying time to save lives - current situation and perspectives
32253318 2020. Effectiveness of convalescent plasma therapy in severe COVID-19 patients
32345485 ä. Treatment for emerging viruses: Convalescent plasma and COVID-19
32380316 ä. Convalescent plasma in Covid-19: Possible mechanisms of action
32359789 ä. COVID-19 Convalescent Plasma: Now Is the Time for Better Science
32359788 ä. Convalescent Plasma: Therapeutic Hope or Hopeless Strategy in the SARS-CoV-2 Pandemic
32217555 2020. Covid-19: FDA approves use of convalescent plasma to treat critically ill patients
| 32369628 2020. Convalescent donor SARS-COV-2-specific cytotoxic T lymphocyte infusion as a possible treatment option for COVID-19 patients with severe disease has not received enough attention till date |
